The IA-2 antibody test detects autoantibodies against insulinoma-associated antigen 2, a protein in the membrane of pancreatic beta-cell secretory granules. It is positive in about 60 percent of pediatric type 1 diabetes at diagnosis, 30 to 40 percent of adult type 1 diabetes, and 10 to 30 percent of LADA cases. IA-2 is most useful as part of a multi-antibody panel with GAD-65 and ZnT8, where the combination detects roughly 95 percent of autoimmune diabetes.
What the IA-2 Antibody Is
Insulinoma-associated antigen 2 (IA-2, also written as IA-2A or ICA-512) is a tyrosine-phosphatase-like protein anchored in the membrane of insulin-containing secretory granules in pancreatic beta cells. Its biological function is not fully understood but appears to involve regulating insulin secretion and granule biogenesis.
In autoimmune diabetes, the immune system recognizes IA-2 as foreign and generates autoantibodies against its cytoplasmic domain. These antibodies do not destroy beta cells directly, but their presence in blood is a reliable marker of the underlying autoimmune attack. The IA-2 protein is structurally related to a homologous molecule called IA-2β (or phogrin), and some assays measure antibodies against both.
Sensitivity by Population
| Population | IA-2 positivity rate | Notes |
|---|---|---|
| New-onset pediatric type 1 diabetes | About 60 percent | Higher in younger children |
| New-onset adolescent T1D | 50 to 60 percent | Often higher titers |
| New-onset adult type 1 diabetes | 30 to 40 percent | Lower than in children |
| LADA | 10 to 30 percent | Lower than GAD-65 in this population |
| Long-standing T1D | 20 to 40 percent | Titers decline more rapidly than GAD-65 |
| Type 2 diabetes | Less than 2 percent | Highly specific when positive |
| First-degree relatives of T1D | 2 to 4 percent | High predictive value combined with other antibodies |
| General population | Less than 1 percent | Very specific — more so than GAD-65 |
When the IA-2 Test Is Ordered
| Clinical situation | Why IA-2 helps |
|---|---|
| New-onset diabetes in a child or adolescent | Part of standard T1D antibody panel |
| New-onset adult diabetes with ambiguous phenotype | Adds specificity to GAD-65 result |
| Negative GAD-65 with high T1D suspicion | Catches cases GAD missed |
| TrialNet relative screening | Part of the validated risk-prediction panel |
| Pre-symptomatic T1D risk stratification | Marks more advanced autoimmunity |
| Pre-pancreas/islet transplant evaluation | Documents pre-transplant antibody status |
Reference Ranges and Interpretation
| Titer | Range (typical) | Interpretation |
|---|---|---|
| Negative | Less than 7.5 U/mL | No detectable IA-2 antibodies (lab-dependent) |
| Borderline | 7.5 to 15 U/mL | Repeat in 4 to 8 weeks; correlate with other antibodies |
| Low positive | 15 to 50 U/mL | Supports autoimmune diabetes diagnosis |
| Moderate positive | 50 to 250 U/mL | Strong evidence of active beta-cell autoimmunity |
| High positive | Greater than 250 U/mL | Aggressive autoimmunity; rapid progression possible |
Reference cutoffs vary by laboratory and assay platform. Always interpret in the context of the lab’s own reported reference range and the broader antibody panel.
How the Test Is Performed
- Sample: serum from a routine venous blood draw
- Fasting required? No — antibody levels are not affected by meals or time of day
- Assay platform: radiobinding assay historically, now mostly ELISA and ECLIA
- Turnaround: typically 5 to 10 days; some reference labs run only weekly batches
- Cost: 80 to 250 dollars self-pay; usually covered with appropriate indication
- Often bundled: many labs offer a “diabetes autoantibody panel” of GAD-65 plus IA-2 plus ZnT8 (sometimes plus anti-insulin) at a discount versus ordering separately
IA-2 in Combination Panels
The diagnostic power of IA-2 increases dramatically when combined with other autoantibodies. Position in a panel:
| Combination | Sensitivity for T1D | Specificity |
|---|---|---|
| GAD-65 alone | 60 to 80 percent | About 95 percent |
| IA-2 alone | 30 to 60 percent | Greater than 98 percent |
| ZnT8 alone | 60 to 80 percent | Greater than 98 percent |
| GAD-65 + IA-2 | About 90 percent | About 99 percent |
| GAD-65 + IA-2 + ZnT8 | About 95 percent | Greater than 99 percent |
| Full panel (+ anti-insulin) | 96 to 98 percent | Greater than 99 percent |
For TrialNet and most prevention trials, the panel of GAD-65 + IA-2 + ZnT8 + anti-insulin is the screening standard.
IA-2 in Type 1 Diabetes Natural History
In the stage-based model of T1D progression:
- Stage 1: two or more autoantibodies positive, glucose still normal
- Stage 2: two or more antibodies plus dysglycemia (impaired fasting glucose, IGT, or rising A1C)
- Stage 3: clinical hyperglycemia meeting diabetes diagnostic criteria
IA-2 antibodies often appear later in this trajectory than GAD-65 or anti-insulin. Their appearance frequently coincides with the transition from stage 1 to stage 2 — making them an important marker of imminent progression. In TrialNet cohorts, individuals with two or more positive antibodies including IA-2 have a 5-year progression risk near 50 percent.
Limitations and Pitfalls
- Lower sensitivity in adults: IA-2 catches only 30 to 40 percent of adult T1D, so it cannot be used alone to rule out autoimmune diabetes.
- Faster decline after diagnosis: IA-2 titers fall off more quickly than GAD-65 in established T1D — by 5 to 10 years, only 20 to 40 percent of patients remain positive.
- Cross-reactive proteins: some assays may pick up antibodies to the related protein IA-2β (phogrin) — this is usually desirable, since phogrin antibodies have similar clinical meaning.
- Negative does not rule out T1D: always pair with GAD-65 and ZnT8.
- Borderline values: repeat in 4 to 8 weeks before drawing conclusions.
- Assay variability: use the same lab when monitoring serial titers.
What Happens After a Positive Result
- Review the rest of the antibody panel (GAD-65, ZnT8, anti-insulin) and calculate the number of positives.
- Check c-peptide to gauge current beta-cell function.
- Confirm diabetes status with fasting glucose, A1C, and/or OGTT.
- If positive in someone not yet diabetic, refer to specialized clinic or TrialNet study for monitoring.
- If positive in established diabetes, reclassify as type 1 or LADA rather than type 2; adjust therapy accordingly.
- Counsel on monitoring for DKA, especially in adults transitioning to insulin.
Related Reading
See our broader guides on detection of prediabetes, GAD-65 antibody testing, ZnT8 antibody testing, islet cell antibodies, and c-peptide.
The Bottom Line
The IA-2 antibody test detects autoantibodies against insulinoma-associated antigen 2, a beta-cell granule membrane protein. It is most sensitive in pediatric type 1 diabetes (about 60 percent) and less so in adults (30 to 40 percent) and LADA (10 to 30 percent). IA-2 antibodies tend to appear later in the autoimmune process than GAD-65, signaling more advanced disease. The test is most powerful as part of a panel with GAD-65 and ZnT8, where the combination detects roughly 95 percent of autoimmune diabetes. Use IA-2 testing in any patient with new-onset diabetes and an ambiguous phenotype, in family members for risk stratification, and as part of the standard T1D evaluation. Talk to your endocrinologist about which autoantibody panel makes sense for your situation.
